News Center

Company news

Media reports

24

2024-05

Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China Received Clearance By NMPA

Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.

Picture Name

21

2024-04

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

April 21, 2024-Kintor Pharma announced that GT20029 China Phase II Trial For AGA Reached Primary Endpoint.

Picture Name

02

2024-04

AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected

Three oncology studies from kintor pharma selected 2024 American Association of Cancer Research Annual Meeting.

Picture Name

13

2024-03

c-Myc Degrader Study Published in Subsidiary Journal of Nature

c-Myc Degrader Study Published in Subsidiary Journal of Nature. The study shows that c-Myc molecular glue compound has great potential.

Picture Name

28

2023-10

Kintor Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine

Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect.

Picture Name

11

2023-10

Kintor Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Suzhou, October 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration (NMPA) for treatment of idiopathic pulmonary fibrosis (IPF).

Picture Name
< 1234...22 > proceed page

Kintor